Drug Profile
Nabitan
Alternative Names: HGP 4; SP 106Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator HG Pars
- Class Analgesics; Antiemetics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting; Pain
Most Recent Events
- 08 Jun 2001 Profile reviewed but no significant changes made
- 03 Feb 1997 No-Development-Reported for Emesis in USA (PO)
- 03 Feb 1997 No-Development-Reported for Pain in USA (PO)